Full Breakdown
AI Technologies Target Clinical Trial Access and Efficiency Across the Globe
By Drooid · · How we work
Rural Access Gap and Paradigm Health’s Screening Platform
Geography has long limited participation in U.S. clinical trials. Approximately 81.7 million Americans live in rural areas, and 86 % of non-metropolitan counties lacked active cancer treatment trials in 2022, versus 44 % of metropolitan counties. A study of nearly 30 000 cancer trial participants found almost three-quarters of rural patients traveled more than 50 miles, compared with 16 % of urban patients.
Paradigm Health’s AI system scans electronic health records far faster than manual methods. The company reports the ability to screen 8 000 times more patients in ten minutes than traditional processes can achieve in a full day, expanding daily capacity from roughly 10 000 to 20 000 screened patients in community and rural health systems. The technology also flags patients with upcoming appointments, enabling timely trial-eligibility conversations.
AstraZeneca–Oracle Global AI Collaboration
On October 20, 2026, AstraZeneca and Oracle Health and Life Sciences announced a non-binding partnership to explore AI-enabled clinical-trial recruitment, patient-safety monitoring, and evidence generation. The collaboration will create a continuous-learning model that links real-world health data with research insights, initially focusing on oncology, cardiovascular, renal, metabolic, respiratory, immunology, and rare-disease areas. Pilot work will begin in Abu Dhabi, targeting hypertension care through a joint effort with local health firm M42.
The agreement emphasizes governance, privacy, and regulatory safeguards; patient-identifiable data will remain with health systems, and each project will proceed only after appropriate legal and ethical reviews.
African Innovation: BioInformatiCo’s Leova Platform
Johannesburg-based BioInformatiCo earned second place in the 2026 Clinical Data Interchange Standards Consortium (CDISC) AI Innovation Challenge with its “Leova” platform, which automates the creation and testing of clinical-trial databases. By converting a typical five-day specialist effort into a single day, Leova reduces manual labor and helps identify protocol-level errors before live enrollment. The tool supports vaccine and infectious-disease trials across sub-Saharan Africa and is preparing a U.S. site launch and European sponsor discussions.
Data & Statistics
- Rural U.S. population: 81.7 million (? 25 % of residents).
- 2022: 86 % of non-metropolitan counties had no active cancer trials; 44 % of metropolitan counties did.
- National Library of Medicine (2025) study: ~75 % of rural participants traveled > 50 miles vs. 16 % of urban participants.
- Paradigm Health AI: 100 000 patients screened in ten minutes (vs. ~12 manually per day).
- Oracle-AstraZeneca partnership: aims to accelerate patient identification across multiple therapeutic areas; first program targets hypertension in Abu Dhabi.
- BioInformatiCo Leova: reduced database testing time from five days to one day; placed second among 19 entries in Use Case 1 of the CDISC challenge.
Verbatim Quotes
- “If you live in a rural area, your likelihood of getting access to best possible care, which could be a clinical trial, is limited,” — Kent Thoelke, CEO of Paradigm Health
- “We can screen 100,000 patients in 10 minutes.” — Kent Thoelke, CEO of Paradigm Health
- “Some of the most important opportunities for AI are in healthcare, where better use of data can help turn scientific innovation into better outcomes for patients,” — Mike Sicilia, CEO of Oracle
What’s Next
The AstraZeneca–Oracle alliance plans to roll out additional AI-driven projects in the United States, Europe, and the Middle East over the coming months, subject to governance approvals. BioInformatiCo intends to launch a U.S. site and seek seed funding for further development of Leova. Paradigm Health continues to integrate its screening engine with community health-system electronic records, aiming to double patient-screening volumes in rural networks.